Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-pKa Polar Moiety

Signaling pathways intersecting with the p21-activated kinases (PAKs) play important roles in tumorigenesis and cancer progression. By recognizing that the limitations of FRAX1036 (1) were chiefly associated with the highly basic amine it contained, we devised a mitigation strategy to address severa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:ACS medicinal chemistry letters 2015-10, Vol.6 (12), p.1241-1246
Hauptverfasser: Ndubaku, Chudi O., Crawford, James J., Drobnick, Joy, Aliagas, Ignacio, Campbell, David, Dong, Ping, Dornan, Laura M., Duron, Sergio, Epler, Jennifer, Gazzard, Lewis, Heise, Christopher E., Hoeflich, Klaus P., Jakubiak, Diana, La, Hank, Lee, Wendy, Lin, Baiwei, Lyssikatos, Joseph P., Maksimoska, Jasna, Marmorstein, Ronen, Murray, Lesley J., O’Brien, Thomas, Oh, Angela, Ramaswamy, Sreemathy, Wang, Weiru, Zhao, Xianrui, Zhong, Yu, Blackwood, Elizabeth, Rudolph, Joachim
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Signaling pathways intersecting with the p21-activated kinases (PAKs) play important roles in tumorigenesis and cancer progression. By recognizing that the limitations of FRAX1036 (1) were chiefly associated with the highly basic amine it contained, we devised a mitigation strategy to address several issues such as hERG activity. The 5-amino-1,3-dioxanyl moiety was identified as an effective means of reducing pKa and logP simultaneously. When positioned properly within the scaffold, this group conferred several benefits including potency, pharmacokinetics, and selectivity. Mouse xenograft PK/PD studies were carried out using an advanced compound, G-5555 (12), derived from this approach. Overall, these studies concluded that dose-dependent pathway modulation was achievable and paves the way for further in vivo investigations of PAK1 function in cancer and other diseases.
ISSN:1948-5875
1948-5875
DOI:10.1021/acsmedchemlett.5b00398